-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Special Symposium on the Basic Science in Hemostasis and Thrombosis

PhD Trainee
Program: Scientific Symposia
Monday, December 11, 2023: 4:30 PM-6:00 PM
Room 30 (San Diego Convention Center)
Denise E. Sabatino, PhD, Children's Hospital of Philadelphia , Herve Falet, PhD, Versiti Blood Research Institute and Rafal Pawlinski, PhD, University of North Carolina
Sabatino: Biomarin Pharmaceutical: Consultancy; Spark Therapeutics: Patents & Royalties; Poseida Therapeutics: Consultancy, Research Funding. Pawlinski: CSL: Consultancy, Research Funding.
This session will highlight three emerging topics in hemostasis and thrombosis research that provide new insights into their respective fields.  In the first presentation, the characterization of a bispecific nanobody or antibody may provide new approaches for treating von Willebrand Disease.  The second presentation will provide insights into the contribution of fibrinogen to thrombosis and how these studies may inform novel strategies for thrombosis management.  In the third presentation, the role of neurotrophins on platelet function and their impact on neurobiology will be discussed. 

Dr. Casari will discuss the heterogeneity of von Willebrand disease, and the challenges faced by patients with von Willebrand disease, highlighting the unmet clinical need for new therapeutic options for these patients. She will then describe how KB-V13A12, a bispecific nanobody that increases von Willebrand factor levels by bridging von Willebrand factor and albumin, was designed and tested. Dr. Casari will also discuss the relevance of using Emicizumab in a subgroup of patients with von Willebrand disease and how they are testing it in murine models.    

Dr. Flick will discuss how quantitative and qualitative changes in circulating fibrinogen or fibrin matrix formation alters thrombogenesis. He will present the novel concept that fibrin(ogen) can be directly targeted to produce porous fibrin clot structures with poor red blood cell retention and enhanced susceptibility to fibrinolysis. Dr. Flick will also summarize the innovative studies demonstrating that selective reduction of circulating fibrinogen levels or inhibition of fibrin formation with a nonpolymerizable fibrinogen variant suppresses arterial and venous thrombosis while maintaining substantial hemostatic potential.  

Dr. Marie Lordkipanidzé will discuss the role of the Brain-Derived Neurotrophic Factor (BDNF) in platelet biology. She will provide an overview of the neurotrophins action on platelets and megakaryocytes, as well as present the regulatory role of α2-macroglobulin on BDNF bioavailability in plasma. Dr. Lordkipanidzé will further discuss the importance of platelet released BDNF in cognitive health.  

If you are attending the meeting in San Diego, following this session, please join ASH leadership and your colleagues at the ASH Networking Reception for the Hemostasis and Thrombosis Community, taking place across the hallway, outside on the East Terrace at the San Diego Convention Center, from 6:00 p.m. - 7:30 p.m.

Caterina Casari, PhD

Inserm Uni, Paris, FRA; Unit 1176 Hemostasis, Inflammation and Thrombosis Lab, Inserm, Le Kremlin-Bicetre, France; University Paris-Saclay, Le Kremlin-Bicetre, France

Matthew J. Flick, PhD

UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC

Marie Lordkipanidzé

Faculte de pharmacie, Universite de Montreal, Montréal, QC, CAN; Research Center, Montreal Heart Institute, Montreal, QC, Canada

See more of: Scientific Symposia